Medicine

Hepatitis E

Hepatitis E is an acute, typically self-limiting viral liver infection caused by the hepatitis E virus (HEV), transmitted primarily via the fecal-oral route through contaminated water, with particular severity in pregnant women.

Hepatitis E

2. Epidemiology

3. Risk Factors

4. Anatomy and Function (Relevant Hepatic Anatomy)

Understanding the clinical features of HEV requires knowledge of hepatic microanatomy:

5. Etiology (Focus on Hong Kong)

6. Pathophysiology

7. Classification

8. Clinical Features

8.2 Symptoms (with Pathophysiological Basis)

The clinical course follows the classic pattern of acute viral hepatitis, divided into three phases [3]:

9. Special Populations

Differential Diagnosis of Hepatitis E

When a patient presents with features suggestive of acute hepatitis — fever, malaise, anorexia, jaundice, RUQ discomfort, deranged LFT with predominant ALT/AST elevation — HEV is just one possibility. The differential diagnosis must be systematically constructed because the clinical presentation of acute hepatitis is largely indistinguishable across etiologies. As the GC lecture slides emphasize: determining the final diagnosis requires history (drug history), clinical presentation, other investigations, and liver biopsy may be required [7].

The key principle: you cannot tell "acute vs acute-on-chronic hepatitis" or distinguish the causative virus by symptoms and signs alone [3]. The clinical presentation of all viral hepatitides overlaps enormously. Diagnosis rests on serological and virological testing.


1. Other Viral Hepatitis (Most Important DDx Category)

This is the most critical category because you cannot clinically distinguish one viral hepatitis from another — serological testing is mandatory.

2. Drug/Toxin-Induced Liver Injury

4. Metabolic / Storage Diseases

5. Vascular Causes

6. Other Infections (Non-Hepatitis Viruses)

These are relevant when HEV is suspected in a pregnant patient (where HEV already carries high mortality):

References

[2] Senior notes: Maksim Medicine Notes.pdf (Viral hepatitis overview table, p.141) [3] Senior notes: Block A - Jaundice after raw oysters_ acute hepatitis.pdf (p.1) [4] Senior notes: Ryan Ho GI.pdf (p.235, HEV section) [5] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p.767, HEV differential diagnosis) [6] Senior notes: Block A - I am a hepatitis B carrier.pdf (p.28, HEV superinfection on chronic HBV) [7] Lecture slides: Gastroenterology Hepatology Introduction to GI:Hepatology investigations from the abnormal.pdf (p.40, p.49) [8] Senior notes: Block A - Gastrointestinal Data Interpretation.pdf (p.2–5) [9] Senior notes: Block A - Abdominal distension_ ascites and cirrhosis.pdf (p.2) [10] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p.738, HAV differential diagnosis — analogous framework) [11] Senior notes: Ryan Ho Respiratory.pdf (p.53, infectious mononucleosis) [12] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf (p.3, causes of ALF) [13] Senior notes: Block A - Introduction to GI_Hepatology investigations (LFT, Endoscopy).pdf (p.15–17) [14] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf (p.2, Wilson disease) [15] Senior notes: Block A - Gastroenterology Interactive Tutorial.pdf (p.2, dual liver disease) [16] Senior notes: Ryan Ho Fundamentals.pdf (p.295, approach to jaundice)

Diagnostic Criteria, Algorithm, and Investigations for Hepatitis E

1. Diagnostic Criteria

Unlike some conditions (e.g., SLE with SLICC criteria, or rheumatic fever with Jones criteria), there is no formal "points-based" diagnostic criteria set for HEV. Instead, diagnosis is established through a combination of:

  1. Compatible clinical presentation — acute hepatitis syndrome (fever, jaundice, elevated transaminases) with appropriate exposure history
  2. Serological confirmation — detection of anti-HEV IgM antibodies
  3. Virological confirmation — detection of HEV RNA by RT-PCR (in serum or stool)
  4. Exclusion of other causes — a critical step emphasized in the GC lecture slides

The diagnosis of HEV is fundamentally a serological + virological diagnosis supported by clinical context and exclusion of alternatives. There is no single pathognomonic clinical feature.

3. Investigation Modalities

3.2 Blood Investigations

3.3 Specific Serological and Virological Tests for HEV

This is where the definitive diagnosis is made.

6. Special Diagnostic Considerations

References

[2] Senior notes: Maksim Medicine Notes.pdf (Viral hepatitis overview table and approach, p.141) [3] Senior notes: Block A - Jaundice after raw oysters_ acute hepatitis.pdf (p.20, HEV diagnosis) [4] Senior notes: Ryan Ho GI.pdf (p.235, HEV diagnosis section) [6] Senior notes: Block A - I am a hepatitis B carrier.pdf (p.28, HEV superinfection) [7] Lecture slides: Gastroenterology Hepatology Introduction to GI:Hepatology investigations from the abnormal.pdf (p.40, p.49) [8] Senior notes: Block A - Gastrointestinal Data Interpretation.pdf (p.2–5, LFT interpretation and viral markers) [17] Lecture slides: GC 239. Viral hepatitis HAV_HBV_HCV_HEV.pdf (p.11, p.20, diagnostic algorithm) [18] Senior notes: Learning_Points_All_Lectures.txt (GI/Hepatology data interpretation learning points) [19] Lecture slides: 1213_DI_GI_Prof_WK_Leung.ppt.pdf (p.14, interpretation of viral hepatitis markers)

Management of Hepatitis E

2. Management of Acute HEV in Immunocompetent Patients

This is the commonest clinical scenario and the management is straightforward.

3. Management of Fulminant HEV (Acute Liver Failure)

Fulminant HEV is rare in the general population but carries high mortality, especially in pregnant women [1] and patients with pre-existing chronic liver disease [1]. The management follows the general principles of acute liver failure (ALF) management [20]:

4. Management of Chronic HEV in Immunosuppressed Patients

This is the second major management scenario and is highly exam-relevant because it is one of the few situations where specific treatment for HEV exists.

5. Prevention

Prevention is a key component of HEV management at the population and individual level.

6. Special Population Management

References

[1] Lecture slides: GC 239. Viral hepatitis HAV_HBV_HCV_HEV.pdf (p.17, p.21, treatment and prevention) [2] Senior notes: Maksim Medicine Notes.pdf (Viral hepatitis overview and management, p.141) [3] Senior notes: Block A - Jaundice after raw oysters_ acute hepatitis.pdf (p.1, p.3, management of symptomatic hepatitis) [5] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p.769–771, treatment, complications, prevention) [20] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf (p.24, ALF management principles)

Complications of Hepatitis E

The complications of HEV span a wide spectrum — from benign, self-resolving cholestasis through to fulminant hepatic failure and death. The likelihood and type of complication depend heavily on the host (immunocompetent vs. immunosuppressed, pregnant vs. non-pregnant, pre-existing liver disease vs. healthy liver). Understanding why each complication occurs requires linking back to the pathophysiology covered earlier.


1. Hepatic Complications

4. Extrahepatic Complications

These are increasingly recognized and are more common in HEV than in HAV. They are thought to result from either direct viral tissue tropism (HEV RNA found in non-hepatic tissues) or immune-mediated mechanisms (molecular mimicry, immune complex deposition).

References

[1] Lecture slides: GC 239. Viral hepatitis HAV_HBV_HCV_HEV.pdf (p.17, p.21) [3] Senior notes: Block A - Jaundice after raw oysters_ acute hepatitis.pdf (p.2, p.3, p.20, p.21) [4] Senior notes: Ryan Ho GI.pdf (p.235, HEV section) [5] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p.769–771, complications and prognosis) [6] Senior notes: Block A - I am a hepatitis B carrier.pdf (p.28, HEV superinfection) [13] Senior notes: Block A - Introduction to GI_Hepatology investigations (LFT, Endoscopy).pdf (p.15, fulminant HEV case) [20] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf (p.12, p.24, ALF complications and ACLF prognostic factors) [21] Lecture slides: Handbook of Internal Medicine 2024.pdf (p.88, ALF definition) [22] Senior notes: Block A - Hematology Data Interpretation.pdf (p.1, hepatitis preceding aplastic anemia)

High Yield Summary

Definition: HEV is a non-enveloped ssRNA virus (family Hepeviridae) causing acute viral hepatitis, transmitted fecal-orally and zoonotically.

Epidemiology: 20M cases/year globally; HK seroprevalence ~33.6%; genotypes 3 and 4 predominate locally (zoonotic from pigs).

Key Risk Factors: Raw/undercooked pork liver (HK classic), contaminated water, shellfish; pregnancy (3rd trimester), immunosuppression, pre-existing CLD.

Pathophysiology: Immune-mediated hepatocyte injury (not direct cytopathic); Kupffer cell damage → endotoxin-mediated injury (explains pregnancy severity); impaired T-cell clearance in immunosuppressed → chronicity.

Clinical Features: Pre-icteric (fever, anorexia, fatigue, diarrhea, RUQ ache, dark urine, pruritus) → Icteric (jaundice, pale stools) → Convalescent. Notable for prominent cholestasis (~20%), extrahepatic manifestations (neuro, renal, hematological).

Critical Differentiators from HAV: Zoonotic reservoir, longer incubation, NO lifelong immunity, CAN cause chronic infection (immunosuppressed), HIGHER mortality (1–2% baseline, 20–25% in pregnancy), MORE cholestatic.

Hong Kong Pearls: "Pork liver congee virus"; rat-HEV first reported in HK; superinfection on chronic HBV is important; all viral hepatitis are notifiable.

High Yield Summary – DDx of Hepatitis E

  1. The clinical presentation of HEV is indistinguishable from other causes of acute hepatitis — diagnosis depends on serology (anti-HEV IgM) and clinical context (exposure history).

  2. In Hong Kong, always consider: (a) HEV superinfection on chronic HBV, (b) dual liver disease (HBV + MASLD + HEV), (c) rat-HEV in immunosuppressed patients.

  3. Key DDx categories: viral (HAV, HBV, HCV, EBV, CMV), drugs/toxins (paracetamol, DILI, TCM, alcohol), autoimmune, metabolic (Wilson), vascular (ischaemic hepatitis, Budd-Chiari), pregnancy-related (HELLP, AFLP).

  4. LFT pattern helps but is not diagnostic: viral hepatitis gives ALT-predominant rise; alcoholic hepatitis gives AST:ALT > 2:1 with AST < 500; ischaemic hepatitis gives rapid rise and fall with elevated LDH.

  5. History is king: food exposure (pork liver → HEV, shellfish → HAV), drug history (paracetamol, TCM), alcohol, pregnancy, hemodynamic status (shock → ischaemic hepatitis), immunosuppression (chronic HEV risk).

High Yield Summary – Diagnosis of Hepatitis E

  1. First-line diagnostic test: Anti-HEV IgM — positive in > 90% of acute cases, coincides with symptom onset, persists ~3 months.

  2. Confirmatory test: HEV RNA RT-PCR (serum or stool) — essential when IgM negative but suspicion high, and mandatory for diagnosing chronic HEV.

  3. GC lecture algorithm: Markedly elevated ALT and AST → Specific serological tests → Exclusion of other causes [17]. HEV RNA is the final step when serology is negative.

  4. Exclusion panel: HBsAg, anti-HAV IgM, anti-HCV, autoantibodies (ANA, anti-SMA, anti-LKM-1), ultrasound, toxicology screen/paracetamol level.

  5. LFT pattern: ALT-predominant rise (ALT > AST), total bilirubin elevated, ± prominent cholestasis (~20%). INR is the critical synthetic function marker.

  6. Monitoring: DAT, Obs Q4h, H'stix BD, daily CBC/LRFT/INR/NH3.

  7. Anti-HEV IgG indicates past infection, NOT acute — does not confer permanent immunity, reinfection possible.

High Yield Summary – Management of Hepatitis E

  1. Acute HEV in immunocompetent patients: No specific treatment. Supportive measures: hydration, electrolyte balance, nutritional balance [1]. No alcohol for 6 months [2][3]. No drugs or herbs hasten recovery [3].

  2. Fulminant HEV: Standard ALF management — ICU care, manage complications, high-volume plasma exchange (washes away cytokines) [20], liver transplantation as final line [20].

  3. Chronic HEV in immunosuppressed: Reduce immunosuppression first → Ribavirin monotherapy × 12 weeks if persistent [2][5]. SVR = absence of HEV RNA 12 weeks after stopping treatment [5].

  4. Ribavirin: Nucleoside analogue; main side effect = hemolytic anemia; absolutely contraindicated in pregnancy (teratogenic).

  5. Prevention: Avoid internal organs (especially pig liver), raw/undercooked meat, shellfish [2]. Hecolin® vaccine developed in China, licensed since 2011, NOT available in HK [1]. No passive immunoprophylaxis [2][5].

  6. Pregnancy paradox: HEV most dangerous in pregnant women (20–25% mortality) but the only antiviral (ribavirin) is contraindicated → management entirely supportive.

High Yield Summary – Complications of Hepatitis E

Hepatic Complications:

  1. Cholestatic hepatitis (~20%) — marked jaundice, pruritus; resolves spontaneously; bilirubin may remain elevated long after ALT normalizes (cholestatic phase).
  2. Acute liver failure — rare overall but devastating; defined by INR ≥ 1.5 + encephalopathy. Risk: pregnant women (20–25% mortality), pre-existing CLD.
  3. Chronic HEV — HEV RNA > 6 months; only in immunosuppressed (transplant, HIV); genotype 3; can progress rapidly to cirrhosis.

Key ALF Complication: Falling ALT + worsening INR = "burnt-out liver" = worse prognosis (distinguish from falling ALT + improving INR = recovery).

Extrahepatic: Neurological (GBS, meningoencephalitis, transverse myelitis), renal (glomerulonephritis), hematological (thrombocytopenia, hemolysis, aplastic anemia), pancreatic, thyroid.

ACLF: HEV superinfection on chronic HBV (common in HK) → acute-on-chronic liver failure. Always check anti-HEV IgM in HBV carriers with acute flares.

Obstetric: Fetal loss, premature delivery, DIC, maternal death.

Reinfection: Possible — antibodies do not confer permanent immunity.

On this page

No Headings